Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Key takeaways in leukemia at ASCO 2022

Eunice Wang • 3 Jun 2022
ASCO 2022
Acute Myeloid Leukemia Leukemia

Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides an overview of key updates in leukemia presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including novel approaches using bispecific antibodies, as well as targeted approaches in acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Eunice Wang

Ziftomenib-induced differentiation syndrome in AML: lessons learned from KOMET-001
11:36
Ziftomenib-induced differentiation syndrome in AML: lessons learned from KOMET-001
Eunice Wang • 18 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals